Jul Aug 2008 APN.pdf - AACP

faculty n e w s
Appointments
• Alice Ceacareanu has been appointed
assistant professor in
the department of pharmacy
practice.
• Eugene D. Morse has been appointed
to chair the Hepatitis
Function Working Group of the
Hepatitis Research Committee
for the NIH/NIAID AIDS Clinical
Trails Group (ACTG).
Promotions
• Joseph P. Balthasar was promoted
to professor of pharmaceutical
sciences.
• Javier G. Blanco was promoted
to associate professor of pharmaceutical
sciences.
• Karl Fiebelkorn was promoted
to clinical associate professor of
pharmacy practice.
Recognition
• In recognition of his unmatched
generosity to the University at
Buffalo School of Pharmacy
and Pharmaceutical Sciences,
the university will name its new
flagship pharmacy building in
honor of venture capitalist, philanthropist
and alumnus John N.
Kapoor, ’72.
•
48
Gayle A. Brazeau presented
University at Buffalo, The
State University of new york
academic Pharmacy now Jul/Aug/Sept 2008
"Harmonization among
Educator-Scientist, Educator-
Clinicians and Clinical Scientists:
Successfully Dovetailing
Industrial Scientist/Clinicians
into our Colleges/Schools" at
the 2008 AACP Institute on
Faculty Recruitment, Retention
and Enrichment in Landsdowne,
Va. on May 21. She also received
the State University of New York
2008 Chancellor's for Excellence
in Faculty Service.
• Linda M. Catanzaro presented
"Addressing Adherence, Toxicity,
and Side Effect Concerns in
ARVNaive Patients," at the International
Association of Physicians
in AIDS Care (IAPAC)
Promoting HAART Adherence
Workshop.
• Robin DiFrancesco presented
"Technology Transfer: Transferring
Chromatography Methods
from Western New York to
Zimbabwe, Africa" at the Spring
2008 Northeast Regional Chromatography
Discussion Group
meeting.
• Karl D. Fiebelkorn was appointed
chairman of the New
York State Pharmacy Conference
(NYSPC) and was awarded the
W. Bruce Philip Certificate of
Commendation by the National
Kappa Psi Pharmaceutical Fraternity.
• Eugene D. Morse, Robin DiFrancesco,
Alan Forrest, Qing Ma
and Daniel A. Brazeau presented
"Effect of CYP3A5 Ploymorphisms
on Atazanavir and Lopinavir
Trough Concentrations in
HIV-Infected Substance Users"
at the 9th International Workshop
of Clinical Pharmacology
of HIV Therapy on April 3-7 in
New Orleans, La.
• Eugene D. Morse, Qing Ma and
Alan Forrest published "Pharmacokinetic
Interaction between
Efavirenz and Dual Protease
Inhibitors in Healthy Volunteers"
in Biopharm Drug Dispos.
• Eugene D. Morse was invited to
serve on the faculty of the 2008
ACCP Research Institute focused
Investigator Training Program
(FIT) and was also invited to
participate in the HRSA Office of
Pharmacy Affairs Patient Safety
and Clinical Pharmacy Collaborative
State Leadership and
Action meeting on May 1.
• Gina M. Zurick published "A
Systematic Approach to Identifying
Drug-Seeking Patients" in
Family Practice Management
April 2008.
University of
california,
San Francisco
Appointments
• Kenneth A. Dill has been elected
into membership of the National
Academy of Sciences.
University of
california,
San diego
Appointments
• James R. Halpert joined the
Skaggs School of Pharmacy
and Pharmaceutical Sciences in
March as professor and associate
dean for scientific affairs.
Caution:
Members at
Work
Members
faculty n e w s
Working
For You!
UNC Professor
Appointed to FDA
Risk Communication
Advisory Committee
Utilizing her more than 15 years of experience in studying
communication between healthcare providers and patients, Dr.
Betsy Sleath, associate professor at the University of North
Carolina at Chapel Hill Eshelman School of Pharmacy, has been
appointed to serve on the Food and Drug Administration (FDA)
Risk Communication Advisory Committee. The group provides
advice to the FDA about how best to communicate to the public
the risks and benefits of FDA-regulated products to ensure their
optimal use.
The 2006 report “The Future of Drug Safety: Promoting and
Protecting the Health of the Public” issued by the Institute of
Medicine (IOM) called for the development a cohesive risk communication
plan. Comprised of 15 voting members that represent
independent experts and public members, the committee's
responsibilities include helping the FDA better understand
the public’s communication needs and priorities; advising the
agency on the development of strategic plans to communicate
product risks and benefits; and making recommendations,
based on current research, on how to craft and deliver risk-andbenefit
messages to audiences.
The committee’s first agenda topic was addressing ways in
which the agency can better communicate information to the
public about product recalls. They looked at a sample FDAissued
press release, for example, and discussed ways to make
the release more understandable for consumers. Should the
agency use a template? Will the message be distributed in multiple
languages? These questions and more were discussed by
the committee, which then makes recommendations to the FDA
on its findings.
Sleath says the broad range in experts’ backgrounds provides
a necessary diversity of knowledge and opinions. Her own
background includes studies of rheumatologist-patient communication
as well as studies of communication at pediatric asthma
clinics and how this impacts the child’s adherence to his/her
medications.
academic Pharmacy now Jul/Aug/Sept 2008 49
—Maureen O’Hara